Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment of the present invention, and (b) a therapeutically effective amount of a combination therapy including bevacizumab and at least one additional therapeutic agent; or a therapeutically effective amount of at least one additional therapeutic agent selected from the group consisting of a COX-2 inhibitor (COXIB), a non-steroidal anti-inflammatory drug (NSAID), a prostaglandin E2 (PGE2) synthase inhibitor, and combinations thereof. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.
1. A composition for treating a human tumor in a subject comprising:
(a) a combination therapy comprising bevacizumab and a topoisomerase inhibitor selected from the group consisting of irinotecan, topotecan hydrochloride, etoposide, doxorubicin, epirubicin, idarubicin, and combinations thereof; and
(b) a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody comprises:
(i) a heavy chain variable region (VH), which comprises the amino acid sequence of SEQ ID NO:5; and
(ii) a light chain variable region (VL), which comprises the amino acid sequence of SEQ ID NO:6;
wherein the monoclonal antibody or antigen binding fragment thereof comprises a constant (Fc) region capable of mediating Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and is capable of binding to one or more of the human tumor endothelial marker 8 (TEM8) sequences of SEQ ID NOs: 10, 20, and 22;
wherein the tumor comprises one or more of human TEM8 expressing tumor cells and human TEM8 expressing tumor stromal cells.
2. The composition according to claim 1 , wherein the human tumor comprises tumor cells and tumor stromal cells expressing human TEM8.
3. The composition according to claim 1 , wherein the human tumor comprises tumor cells or tumor stromal cells expressing human TEM8.
4. The composition according to claim 1 , wherein the human tumor is colon cancer.
5. The composition according to claim 1 , wherein the monoclonal antibody or antigen binding fragment thereof comprises:
(1) a VH polypeptide encoded by:
(SEQ ID NO: 15)
gaggtgcagctggtggagtctgggggaggcgtggtccagcctgggaggtc
cgtgagactctcctgtgcagcctctggattcaccttcagtacctatacta
tgcactgggtccgccaggctccaggcaaggggctggagtgggtggcaatt
atctcaaatgatggaagcaataagtactacgcagaccccgtgaggggccg
attcaccatctccagagacaattccaagaacacgctgtatctgcaaatga
acagcctgagagctgaggacacggctgtgtattactgtgtacgtggcagc
agctggtatcgcggaaattggttcgacccctggggccagggaaccctggt
caccgtgagctca
and
(2) a VL polypeptide encoded by:
(SEQ ID NO: 16)
gacatccagatgacccagtctccatcctccctgtctgcatctgtaggaga
cagagtcaccatcgcttgccgggcaagtcagaccattagtaggtatttaa
attggtatcagcagaaaccagggaaagcccctaagctcctgatctatgct
gcatccagtttgcaaagtggggtctcatcaaggttcagtggcagtggatc
tgggacagagttcactctcaccatcagcagtctgcagcctgaagattttg
caacttatttctgtcaacagacttacagtcccccgatcaccttcggccaa
gggacacgactggagattaaacga.
6. The composition according to claim 1 , further comprising at least one therapeutic agent selected from the group consisting of fluoropyrimidine, oxaliplatin, interferon-α(2a), paclitaxel, carboplatin, and FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin).